SCHEMBL4152883

SCHEMBL4152883

Cc1ccc(NC(=O)c2ccnc3[nH]c(-c4cccc(Cl)c4)nc23)cn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 4/20 0.52
PIK3CA P42336 2/20 0.46
MTOR P42345 2/20 0.46
BRAF P15056 1/20 0.45
CYP11B2 P19099 1/20 0.43
PARP1 P09874 1/20 0.43
PIN1 Q13526 1/20 0.43
TP53 P04637 1/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
CSF1R P07333 1/20 0.42
MGAM O43451 1/20 0.42
GAA P10253 1/20 0.42
SI P14410 1/20 0.42
MGAM2 Q2M2H8 1/20 0.42
SGMS2 Q8NHU3 1/20 0.41
MAPK10 P53779 1/20 0.41
NPY5R Q15761 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
KCNQ3 O43525 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4169206 0.89 GSK3B (0.59) GSK3BPIK3CAMTORBRAFMGAM
SCHEMBL4149991 0.88 GSK3B (0.60) GSK3BPIK3CAMTORCYP11B2PARP1
SCHEMBL4162865 0.87 GSK3B (0.56) GSK3BPIK3CAMTORTP53POLB
SCHEMBL13778234 0.87 GSK3B (0.55) GSK3BPIK3CAMTORBRAFPARP1
SCHEMBL4164597 0.84 GSK3B (0.59) GSK3BPIK3CAMTORGAAKCNQ3
SCHEMBL4152791 0.83 GSK3B (0.73) GSK3BPIK3CAMTORPARP1GAA
SCHEMBL4152722 0.83 GSK3B (0.60) GSK3BPARP1PIN1MGAMGAA
SCHEMBL4159232 0.80 GSK3B (0.59) GSK3BPIK3CAMTORKCNQ3KCNQ2
SCHEMBL4162649 0.80 GSK3B (0.58) GSK3BPIK3CAMTORBRAFPARP1
SCHEMBL4160365 0.80 GSK3B (0.50) GSK3BPIK3CAMTORTP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 GSK3B 1/4885PIK3CA 64/4885MTOR 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.